View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
August 1, 2019updated 12 Jul 2022 12:27pm

Translate Bio’s mRNA candidate produces mixed results in CF trial

Translate Bio has reported positive interim data from a Phase I/II clinical trial of its mRNA candidate MRT5005 for the treatment of cystic fibrosis (CF) patients.

Translate Bio has reported positive interim data from a Phase I/II clinical trial of its mRNA candidate MRT5005 for the treatment of cystic fibrosis (CF) patients.

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

Developed to target the disease’s underlying cause, MRT5005 delivers mRNA that encodes fully functional cystic fibrosis transmembrane conductance regulator (CFTR) protein to lung cells.

The drug candidate, formulated for nebulisation, is not dependent on the patient’s underlying genetic mutation.

In the single ascending dose (SAD) portion of the safety and efficacy trial, 12 patients received an 8mg, 16mg, or 24mg dose of MRT5005 and were followed for one-month after the treatment period.

The product was found to be generally well-tolerated at low and mid-dose levels, without any serious adverse events with any dose. The most common adverse events up to day 29 of the study were cough and headache.

All treatment-emergent adverse events (TEAEs) were observed to be mild to moderate, and no treatment-emergent serious adverse events (SAEs) have been reported.

Analysis for primary lung function measure, ppFEV1, revealed no marked improvements in the pooled 8mg dose and placebo arms.

Three patients treated with the 16mg dose showed maximal ppFEV1 elevations of 11.1%, 13.6%, and 22.2%, for a mean maximum increase from 15.7% baseline in the eight-day period post-dosing.

Of these three patients, two received a stable CFTR modulator therapy for a minimum of 28 days, while the third had a genotype that could not be addressed with the CFTR modulator treatment.

One participant on the 24mg dose of MRT5005 reached a maximum increase in ppFEV1 from baseline of 21.4% and two patients did not achieve a marked increase.

Translate Bio CEO Ronald Renaud said: “These encouraging interim results represent a milestone in the mRNA development landscape as this is the first time an mRNA therapeutic has been evaluated for its potential to treat a genetic disease.”

Based on these findings, the company intends to evaluate a 20mg dose in the SAD portion.

The multiple ascending dose (MAD) portion of the trial is ongoing and will see amendments to include 12mg and 20mg cohorts. This portion will not involve a 24mg cohort.

All new cohorts will enrol four patients each. Top-line data from the 20mg SAD and the MAD portion is expected to be reported next year.

Related Companies

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena